BIOGEN INC. Deferred Income Tax Liabilities, Net
BIOGEN INC. (BIIB) had Deferred Income Tax Liabilities, Net of $483.50 million as of 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredIncomeTaxLiabilitiesNet · last filed 2026-04-29
- 2026-03-31: Deferred Income Tax Liabilities, Net $483.50M.
- 2025-12-31: Deferred Income Tax Liabilities, Net $507.60M.
- 2025-09-30: Deferred Income Tax Liabilities, Net $358.10M.
- 2025-06-30: Deferred Income Tax Liabilities, Net $118.30M.
| Period end | Deferred Income Tax Liabilities, Net |
|---|---|
| 2026-03-31 | $483.50M 10-Q · filed 2026-04-29 |
| 2025-12-31 | $507.60M 10-Q · filed 2026-04-29 |
| 2025-09-30 | $358.10M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $118.30M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $133.20M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $190.50M 10-K · filed 2026-02-06 |
| 2024-09-30 | $882.40M 10-Q · filed 2024-10-30 |
| 2024-06-30 | $590.60M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $658.10M 10-Q · filed 2024-04-24 |
| 2023-12-31 | $641.80M 10-K · filed 2025-02-12 |
| 2023-09-30 | $728.10M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $143.90M 10-Q · filed 2023-07-25 |
| 2023-03-31 | $251.30M 10-Q · filed 2023-04-25 |
| 2022-12-31 | $334.70M 10-K · filed 2024-02-14 |
| 2022-09-30 | $328.90M 10-Q · filed 2022-10-25 |
| 2022-06-30 | $480.60M 10-Q · filed 2022-07-20 |
| 2022-03-31 | $571.20M 10-Q · filed 2022-05-03 |
| 2021-12-31 | $694.50M 10-K · filed 2023-02-15 |
| 2021-09-30 | $774.70M 10-Q · filed 2021-10-20 |
| 2021-06-30 | $918.90M 10-Q · filed 2021-07-22 |
| 2021-03-31 | $966.70M 10-Q · filed 2021-04-22 |
| 2020-12-31 | $1.03B 10-K · filed 2022-02-03 |
| 2020-09-30 | $1.12B 10-Q · filed 2020-10-21 |
| 2020-06-30 | $1.46B 10-Q · filed 2020-07-22 |
| 2020-03-31 | $2.72B 10-Q · filed 2020-04-23 |
| 2019-12-31 | $2.81B 10-K · filed 2021-02-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |